keyword
MENU ▼
Read by QxMD icon Read
search

Free psa

keyword
https://www.readbyqxmd.com/read/28643748/diagnostic-efficacy-of-free-prostate-specific-antigen-total-prostate-specific-antigen-ratio-for-the-diagnosis-of-prostate-cancer-in-low-concentration-%C3%A2-4-ng-ml-and-intermediate-levels-of-total-prostate-specific-antigen-4-01-10-0-ng-ml
#1
Selahattin Caliskan
AIM OF STUDY: Serum prostate-specific antigen (PSA) is a useful tumor biomarker for prostate cancer (PCa) diagnosis. In this study, I aimed to compare the free/total PSA (fPSA%) with PSA alone for their usefulness in diagnosis for PCa. METHODS: The patients who underwent prostate biopsy between January 2010 and January 2015 were evaluated retrospectively. Data were expressed as a mean + standard error and P < 0.05 as considered with statistical significance (Med Calc 14...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28636187/dual-labeled-chemiluminescence-enzyme-immunoassay-for-simultaneous-measurement-of-total-prostate-specific-antigen-tpsa-and-free-prostate-specific-antigen-fpsa
#2
Lixia Zhao, Dan Wang, Gen Shi, Ling Lin
The specificity for early diagnostic of prostate-specific antigen (PSA) is low because the current technology mostly allows the detection of only one biomarker at one time. In this work, a dual-labeled chemiluminescence enzyme immunoassay (CLEIA) for simultaneous measurement of total PSA (TPSA) and free PSA (FPSA) was proposed. Anti-PSA McAb (Mab1) was immobilized on a microplate as the solid phase, horseradish peroxidase (HRP)-labeled anti-TPSA monoclonal antibody (McAb2) and alkaline phosphatase (ALP)-labeled anti-FPSA McAb3 were used as detection antibodies...
June 21, 2017: Luminescence: the Journal of Biological and Chemical Luminescence
https://www.readbyqxmd.com/read/28635569/stratification-model-based-on-early-postprostatectomy-prostate-specific-antigen-kinetics-may-help-to-reduce-the-risk-of-overtreatment-in-candidates-for-adjuvant-radiotherapy
#3
Stepan Vesely, Ladislav Jarolim, Marek Schmidt, Joana Do Carmo Silva, Katerina Duskova, Marko Babjuk
OBJECTIVE: The aim of this study was to construct a stratification model based on early postoperative kinetics of prostate-specific antigen (PSA) to select the most suitable high-risk patients for early intervention after radical prostatectomy (RP). MATERIALS AND METHODS: The study evaluated 205 men who had undergone RP without any adjuvant treatment. All of the patients had positive surgical margins, extracapsular extension and/or seminal vesicle invasion. The patients underwent multiple ultrasensitive PSA measurements on days 14, 30, 60 and 90 after RP, and subsequently at 3 month intervals...
February 24, 2017: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/28632486/randomized-noncomparative-phase-ii-trial-of-early-switch-from-docetaxel-to-cabazitaxel-or-vice-versa-with-integrated-biomarker-analysis-in-men-with-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer
#4
Emmanuel S Antonarakis, Scott T Tagawa, Giuseppe Galletti, Daniel Worroll, Karla Ballman, Marie Vanhuyse, Guru Sonpavde, Scott North, Costantine Albany, Che-Kai Tsao, John Stewart, Atef Zaher, Ted Szatrowski, Wei Zhou, Ada Gjyrezi, Shinsuke Tasaki, Luigi Portella, Yang Bai, Timothy B Lannin, Shalu Suri, Conor N Gruber, Erica D Pratt, Brian J Kirby, Mario A Eisenberger, David M Nanus, Fred Saad, Paraskevi Giannakakou
Purpose The TAXYNERGY trial ( ClinicalTrials.gov identifier: NCT01718353) evaluated clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of sensitivity or resistance to taxanes in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer. Patients and Methods Patients were randomly assigned 2:1 to docetaxel or cabazitaxel. Men who did not achieve ≥ 30% prostate-specific antigen (PSA) decline by cycle 4 (C4) switched taxane. The primary clinical endpoint was confirmed ≥ 50% PSA decline versus historical control (TAX327)...
June 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28624848/-177-lu-psma-617-radioligand-therapy-and-outcome-in-patients-with-metastasized-castration-resistant-prostate-cancer
#5
Axel Bräuer, Lena Sophie Grubert, Wolfgang Roll, Andres Jan Schrader, Michael Schäfers, Martin Bögemann, Kambiz Rahbar
PURPOSE: Radioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of metastasized castration-resistant prostate cancer (mCRPC) in the last decade and show promising response rates and a favourable toxicity profile. The aim of this study was to evaluate the overall survival (OS) and to identify parameters predicting outcome in mCRPC patients treated with (177)Lu-PSMA-617. METHODS: Between December 2014 and January 2017, 59 consecutive patients (median age 72 years; interquartile range, (IQR, 66-76 years) with mCRPC, who had been treated with at least one next-generation antihormonal drug as well as chemotherapy, were included in this study...
June 17, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28623636/eleven-year-management-of-prostate-cancer-patients-on-active-surveillance-what-have-we-learned
#6
Cristina Marenghi, Maria Francesca Alvisi, Federica Palorini, Barbara Avuzzi, Fabio Badenchini, Nice Bedini, Lara Bellardita, Davide Biasoni, Davide Bosetti, Alessandra Casale, Mario Catanzaro, Maurizio Colecchia, Letizia De Luca, Simona Donegani, Paola Dordoni, Rodolfo Lanocita, Massimo Maffezzini, Tiziana Magnani, Julia Menichetti, Antonella Messina, Sara Morlino, Biagio Paolini, Tiziana Rancati, Silvia Stagni, Antonio Tesone, Tullio Torelli, Edoardo Tulli Baldoin, Marta Vaiani, Sergio Villa, Silvia Villa, Nadia Zaffaroni, Nicola Nicolai, Roberto Salvioni, Riccardo Valdagni
PURPOSE: To evaluate the outcomes of active surveillance (AS) on patients with low-risk prostate cancer (PCa) and to identify predictors of disease reclassification. METHODS: In 2005, we defined an institutional AS protocol (Sorveglianza Attiva Istituto Nazionale Tumori [SAINT]), and we joined the Prostate Cancer Research International: Active Surveillance (PRIAS) study in 2007. Eligibility criteria included clinical stage ≤T2a, initial prostate-specific antigen (PSA) <10 ng/mL, and Gleason Pattern Score (GPS) ≤3 + 3 (both protocols); ≤25% positive cores with a maximum core length containing cancer ≤50% (SAINT); and ≤2 positive cores and PSA density <0...
June 14, 2017: Tumori
https://www.readbyqxmd.com/read/28622831/impact-of-postoperative-radiotherapy-in-men-with-persistently-elevated-prostate-specific-antigen-after-radical-prostatectomy-for-prostate-cancer-a-long-term-survival-analysis
#7
Giorgio Gandaglia, Stephen A Boorjian, William P Parker, Emanuele Zaffuto, Nicola Fossati, Marco Bandini, Paolo Dell'Oglio, Nazareno Suardi, Francesco Montorsi, R Jeffrey Karnes, Alberto Briganti
BACKGROUND: Prostate cancer (PCa) patients with prostate-specific antigen (PSA) persistence after radical prostatectomy (RP) are at increased risk of mortality, although the natural history of these men is heterogeneous and the optimal management has not been established. OBJECTIVE: To develop a model to predict cancer-specific mortality (CSM) and to test the impact of radiotherapy (RT) on survival in this setting. DESIGN, SETTING, AND PARTICIPANTS: We identified 496 patients treated with RP and lymph node dissection at two referral centers between 1994 and 2014 who had PSA persistence, defined as a PSA level between 0...
June 13, 2017: European Urology
https://www.readbyqxmd.com/read/28622770/intensity-modulated-radiation-therapy-from-70gy-to-80gy-in-prostate-cancer-six-year-outcomes-and-predictors-of-late-toxicity
#8
Maria Jolnerovski, Julia Salleron, Véronique Beckendorf, Didier Peiffert, Anne-Sophie Baumann, Valérie Bernier, Sandrine Huger, Vincent Marchesi, Ciprian Chira
OBJECTIVE: To report grade ≥2 overall late rectal and urinary toxicities in patients (pts) with prostate cancer treated by intensity-modulated radiotherapy (IMRT) at 3 dose-levels. Identify predictors of radiation toxicity and report biochemical progression free survival (bPFS). METHODS: A total of 277 pts were treated with 70Gy (10.8%), 74Gy (63.9%) and 80 Gy (25.3%) using IMRT without pelvic irradiation were analyzed. Short or long-course androgen deprivation therapy (ADT) was allowed in 46...
June 16, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28618395/erg-overexpression-plus-slc45a3-prostein-and-pten-expression-loss-strong-association-of-the-triple-hit-phenotype-with-an-aggressive-pathway-of-prostate-cancer-progression
#9
Silvia Hernández-Llodrà, Nuria Juanpere, Silvia de Muga, Marta Lorenzo, Joan Gil, Alba Font-Tello, Laia Agell, Raquel Albero-González, Laura Segalés, José Merino, Laia Serrano, Lluís Fumadó, Lluís Cecchini, Josep Lloreta Trull
TMPRSS2 and SLC45A3 rearrangements may coexist in the same tumor. ERG rearrangements and PTEN loss are concomitant events in prostate cancer (PrCa), and can cooperate in progression. We have reported that mRNA expression of TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss define an aggressive tumor subset. The aim of this study has been to validate these results by immunohistochemistry in a large cohort of tumors. ERG, SLC45A3 and PTEN immunostaining and their association with pathological features and PSA progression-free survival were analyzed in 220 PrCa (PSMAR-Biobank, Barcelona, Spain)...
May 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28615058/long-term-prognostic-significance-of-rising-psa-levels-following-radiotherapy-for-localized-prostate-cancer-focus-on-overall-survival
#10
Carla Freiberger, Vanessa Berneking, Thomas-Alexander Vögeli, Ruth Kirschner-Hermanns, Michael J Eble, Michael Pinkawa
BACKGROUND: The aim of this study was to evaluate the long-term prognostic significance of rising PSA levels, particularly focussing on overall survival. METHODS: Two hundred ninety-five patients with localized prostate cancer were either treated with low-dose-rate (LDR) brachytherapy with I-125 seeds as monotherapy (n = 94; 145Gy), high-dose-rate (HDR) brachytherapy with Ir-192 as a boost to external beam RT (n = 66; 50.4Gy in 1.8Gy fractions EBRT + 18Gy in 9Gy fractions HDR) or EBRT alone (70...
June 14, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28613202/-comparison-of-two-on-line-risk-calculators-versus-the-detection-of-circulating-prostate-cells-for-the-detection-of-high-risk-prostate-cancer-at-first-biopsy
#11
Nigel P Murray, Cynthia Fuentealba, Eduardo Reyes, Omar Jacob
OBJECTIVE: The limitations of total serum PSA values remains problematic; nomograms may improve the prediction of a positive prostate biopsy (PB). We compare in a prospective study of Chilean men with suspicion of prostate cancer due to an elevated total serum PSA and/or abnormal digital rectal examination, the use of two on-line nomograms with the detection of primary malignant circulating prostate cells (CPCs) to predict a positive PB for high risk prostate cancer. METHODS: Consecutive men with suspicion of prostate cancer underwent 12 core TRUS prostate biopsy...
June 2017: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/28607597/psa-and-prostate-health-index-based-prostate-cancer-screening-in-a-hereditary-migration-complicated-population-implications-in-precision-diagnosis
#12
Mariyam Akizhanova, Elzira E Iskakova, Valdemir Kim, Xiao Wang, Roman Kogay, Aiym Turebayeva, Qinglei Sun, Ting Zheng, Shenghui Wu, Lixia Miao, Yingqiu Xie
Precision diagnosis requires specific markers for differential ethnic populations. Prostate-Specific Antigen (PSA) level (threshold of 4ng/ml) has been widely used to screen prostate cancer and as reference of pro-biopsy but false diagnosis frequently occurs. Prostate health Index (PHI) is a new diagnosis marker which combines PSA, free PSA and p2PSA4. Overall the PCa screening database is lacking in Kazakhstani patients. We analyzed the PSA levels and Gleason scores of 222 biopsies collected in 2015 in Almaty area, Kazakhstan approved by institutional ethics board...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28606735/neutrophil-to-lymphocyte-ratio-in-castration-resistant-prostate-cancer-patients-treated-with-daily-oral-corticosteroids
#13
Niven Mehra, Adam Sharp, David Lorente, David Dolling, Semini Sumanasuriya, Bernadette Johnson, David Dearnaley, Chris Parker, Johann de Bono
BACKGROUND: The neutrophil to lymphocyte ratio (NLR) has been shown to be highly prognostic across many tumor types, and predictive of treatment outcome in advanced prostate cancer, and has been postulated to be an indirect measure of tumor inflammation. We evaluated the effect of low-dose steroids on NLR in men suffering from castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: The NLR was evaluated in a prospective randomized phase II trial that compared prednisolone 5 mg twice daily and dexamethasone 0...
May 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28605139/clinical-implications-of-pretreatment-inflammatory-biomarkers-as-independent-prognostic-indicators-in-prostate-cancer
#14
Zhaohui Sun, Ying Ju, Fuyan Han, Xiya Sun, Fang Wang
OBJECTIVES: Research on the relationship between inflammatory biomarkers and malignant tumors has become a hotspot. Many studies have demonstrated that neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and red blood cell distribution width (RDW) could act as independent prognostic indicators for several solid tumors. This study aimed to evaluate the clinical implications of pretreatment inflammatory biomarkers, including NLR, PLR, and RDW as independent prognostic indicators in prostate cancer (PCa)...
June 12, 2017: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/28602051/yes-associated-protein-expression-is-correlated-to-the-differentiation-of-prostate-adenocarcinoma
#15
Myung-Giun Noh, Sung Sun Kim, Eu Chang Hwang, Dong Deuk Kwon, Chan Choi
Background: Yes-associated protein (YAP) in the Hippo signaling pathway is a growth control pathway that regulates cell proliferation and stem cell functions. Abnormal regulation of YAP was reported in human cancers including liver, lung, breast, skin, colon, and ovarian cancer. However, the function of YAP is not known in prostate adenocarcinoma. The purpose of this study was to investigate the role of YAP in tumorigenesis, differentiation of the carcinoma, and prognosis of prostate adenocarcinoma...
June 9, 2017: Journal of Pathology and Translational Medicine
https://www.readbyqxmd.com/read/28599663/salvage-robotic-sbrt-for-local-prostate-cancer-recurrence-after-radiotherapy-preliminary-results-of-the-oscar-lambret-center
#16
Thomas Leroy, Thomas Lacornerie, Emilie Bogart, Philippe Nickers, Eric Lartigau, David Pasquier
BACKGROUND: Currently, there is no standard option for local salvage treatment for local prostate cancer recurrence after radiotherapy. Our objective was to investigate the feasibility and efficiency of Robotic Stereotactic Body Radiation Therapy (SBRT) in this clinical setting. METHODS/MATERIALS: We retrospectively reviewed patients who were treated at our institution with SBRT for local prostate cancer recurrence after External Beam Radiation Therapy (EBRT) or brachytherapy...
June 9, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28593167/correlation-between-postoperative-prostate-specific-antigen-and-biochemical-recurrence-in-positive-surgical-margin-patients-single-surgeon-series
#17
Won Ik Seo, Pil Moon Kang, Jang Ho Yoon, Wansuk Kim, Jae Il Chung
BACKGROUND: To evaluate the relationship between postoperative prostate-specific antigen (PSA) levels and biochemical recurrence (BCR) after radical prostatectomy, especially in patients with positive surgical margins (PSMs). MATERIALS AND METHODS: A total of 144 patients who underwent radical prostatectomies performed by a single surgeon without any neoadjuvant or adjuvant treatment were analyzed. Differences in clinicopathological factors were compared by surgical margin status, and the relationship between postoperative PSA level and BCR in patients with PSMs was evaluated...
June 2017: Prostate International
https://www.readbyqxmd.com/read/28588730/conversion-to-monotherapy-with-luteinizing-hormone-releasing-hormone-agonist-or-orchiectomy-after-reaching-psa-nadir-following-maximal-androgen-blockade-is-able-to-prolong-progression-free-survival-in-patients-with-metastatic-prostate-cancer-a-propensity-score
#18
Gyeong Eun Min, Hanjong Ahn
The present study evaluated androgen deprivation methods to determine the approach that most improves the progression-free survival (PFS) of patients with metastatic prostate cancer. Patients had received continuous maximal androgen blockade (MAB) or monotherapy [luteinizing-hormone releasing hormone (LHRH) agonist or orchiectomy] following the reaching of the prostate specific antigen (PSA) nadir. The medical records of 293 patients who received MAB following a diagnosis of metastatic prostate cancer were retrospectively reviewed...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28586945/low-dose-rate-brachytherapy-versus-cryotherapy-in-low-and-intermediate-risk-prostate-cancer
#19
Matthew M Gestaut, Wendi Cai, Shilpa Vyas, Belur J Patel, Salman A Hasan, Yolanda MunozMaldonado, Niloyjyoti Deb, Gregory Swanson
PURPOSE: Cryotherapy and brachytherapy are definitive local treatment options for low- to intermediate-risk prostate cancer. There are both prospective and retrospective data for brachytherapy, but the use of cryotherapy has been limited primarily to single-institution retrospective studies. Currently, no published evidence has compared low-dose-rate brachytherapy versus cryotherapy. METHODS AND MATERIALS: Institutional review board approval was obtained to conduct a retrospective chart review of consecutive patients treated at our institution from 1990 to 2012...
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28583553/living-donor-kidney-transplantation-after-brachytherapy-for-prostate-cancer-case-report
#20
S Harada, H Ushigome, K Masuda, T Matsuyama, T Nakamura, K Koshino, T Iida, S Nobori, N Yoshimura
INTRODUCTION: There is no obvious criterion about kidney transplantation for patients with pretransplant malignancy. Minimum tumor-free waiting periods differ according to type of cancer, staging, site of occurrence, response to therapy, and risk of cancer recurrence. We report a case of living donor kidney transplantation (LDKT) in a patient after brachytherapy for prostate cancer. CASE REPORT: The patient was a 65-year-old man with chronic kidney disease due to chronic glomerular nephritis...
June 2017: Transplantation Proceedings
keyword
keyword
25554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"